US · RIGL · BIOTECHNOLOGY
Rigel Pharmaceuticals, Inc. (RIGL) intrinsic value and stock valuation
$40.09as of 2026-11-21 · Mkt cap 748.96M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Rigel Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values RIGL with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from RIGL’s statements →
Rigel Pharmaceuticals, Inc. Graham Number
Graham Number: $99.96d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Corvus Pharmaceuticals, Inc. (CRVS) $9.67
- Olema Pharmaceuticals, Inc. (OLMA) $7.02
- Omeros Corporation (OMER) $13.21
- 4D Molecular Therapeutics, Inc. (FDMT) $10.23
- Prothena Corporation plc (PRTA) $8.22
- Akebia Therapeutics, Inc. (AKBA) $0.39
- Bicycle Therapeutics plc (BCYC) $2.90
- Gossamer Bio, Inc. (GOSS) $10.72
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M |
| Operating income | $125.5M | $24.2M | -$-20.49M | -$-55.55M | -$-12.5M |
| Net income | $367M | $17.5M | -$-25.09M | -$-58.57M | -$-17.91M |
| EPSd | $19.5M | $988.1K | -$-1.44M | -$-3.4M | -$-1.05M |
| Operating cash flow | $75.7M | $31.5M | -$-5.74M | -$-73.76M | $5.88M |
| Capital expenditure | $0.00 | -$-400K | -$-15M | -$-450K | -$-630K |
| Free cash flow | $75.7M | $31.1M | -$-20.74M | -$-74.21M | $5.25M |
| Total assets | $513.6M | $164M | $117.2M | $134.3M | $167.3M |
| Total debt | $53.3M | $60M | $60.6M | $41.6M | $30.6M |
| Net debt | $12.7M | $3.22M | $27.8M | $17.1M | $11.7M |
| Total equity | $391.5M | $3.29M | -$-28.64M | -$-13.62M | $30.4M |
| Cash and short-term investments | $155M | $77.3M | $56.9M | $58.2M | $125M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M |
| Cost of revenue | $19.6M | $18.7M | $7.11M | $1.75M | $1.08M |
| Gross profit | $274.7M | $160.6M | $109.8M | $118.5M | $148.2M |
| Research and development expenses | $33.3M | $23.4M | $24.5M | $60.3M | $65.2M |
| Selling, general and administrative expenses | $115.9M | $113.1M | $105.7M | $112.5M | $91.9M |
| Other expenses | $0.00 | $0.00 | $0.00 | $1.32M | $3.52M |
| Operating expenses | $149.2M | $136.4M | $130.3M | $174M | $160.7M |
| Cost and expenses | $168.8M | $155.1M | $137.4M | $175.8M | $161.7M |
| Interest income | $3.68M | $2.09M | $2.27M | $680K | $50K |
| Interest expense | $7.32M | $7.92M | $6.87M | $3.71M | $4.86M |
| Depreciation and amortization | $2.42M | $2.23M | $1.24M | $1M | $1.16M |
| Ebitda | $131.6M | $28.5M | -$-16.98M | -$-53.87M | -$-11.29M |
| Operating income | $125.5M | $24.2M | -$-20.49M | -$-55.55M | -$-12.5M |
| Total other income/expenses, net | -$-3.64M | -$-5.83M | -$-4.6M | -$-3.02M | -$-4.81M |
| Income before tax | $121.8M | $18.4M | -$-25.09M | -$-58.57M | -$-17.31M |
| Income tax expense | -$-245.2M | $880K | $0.00 | $0.00 | $600K |
| Net income | $367M | $17.5M | -$-25.09M | -$-58.57M | -$-17.91M |
| Weighted average shares outstanding | $18M | $17.6M | $17.4M | $17.2M | $17.1M |
| Weighted average diluted shares outstanding | $18.8M | $17.7M | $17.4M | $17.2M | $17.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $155M | $77.3M | $56.9M | $58.2M | $125M |
| Net receivables | $51.8M | $41.6M | $30.6M | $40.3M | $15.5M |
| Inventory | $11.5M | $6M | $5.52M | $9.12M | $6.62M |
| Total current assets | $240.2M | $135.1M | $99.3M | $115.9M | $154.5M |
| Property, plant and equipment, net | $920K | $340K | $1.03M | $2.79M | $11.9M |
| Goodwill and intangible assets | $24.8M | $27.1M | $13.9M | $15M | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $273.4M | $28.9M | $18M | $18.4M | $12.9M |
| Total assets | $513.6M | $164M | $117.2M | $134.3M | $167.3M |
| Accounts payable | $7.19M | $3.34M | $7.14M | $22.5M | $3.79M |
| Short-term debt | $30.4M | $7.56M | $7.92M | $1.13M | $9.89M |
| Deferred revenue | $1.35M | $27.8M | $17M | $13.5M | $10.5M |
| Total current liabilities | $99.2M | $63.3M | $53.3M | $65.2M | $63.6M |
| Long-term debt | $22.9M | $52.4M | $52.7M | $40.4M | $20.7M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $22.9M | $97.4M | $92.6M | $82.7M | $73.4M |
| Capital lease obligations | $400K | $280K | $980K | $2.1M | $10.7M |
| Total liabilities | $122.1M | $160.7M | $145.9M | $147.9M | $137M |
| Common stock | $20K | $20K | $20K | $170K | $170K |
| Retained earnings | -$-1.02B | -$-1.39B | -$-1.41B | -$-1.38B | -$-1.32B |
| Accumulated other comprehensive income (loss) | $180K | $10K | $10K | -$-150K | -$-100K |
| Total equity | $391.5M | $3.29M | -$-28.64M | -$-13.62M | $30.4M |
| Total investments | $114.4M | $20.6M | $24.2M | $33.8M | $106.1M |
| Total debt | $53.3M | $60M | $60.6M | $41.6M | $30.6M |
| Net debt | $12.7M | $3.22M | $27.8M | $17.1M | $11.7M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $367M | $17.5M | -$-25.09M | -$-58.57M | -$-17.91M |
| Depreciation and amortization | $2.42M | $2.23M | $1.24M | $1M | $1.16M |
| Stock-based compensation | $12.7M | $12.4M | $8.81M | $12.4M | $9.49M |
| Change in working capital | -$-19.51M | $150K | $9.52M | -$-29.05M | $9.72M |
| Accounts receivable | -$-10.15M | -$-11.06M | $9.77M | -$-24.85M | $500K |
| Inventory | -$-5.63M | $760K | $1.17M | -$-2.38M | -$-4.88M |
| Accounts payable | $3.85M | -$-3.8M | -$-370K | $3.79M | $40K |
| Net cash provided by operating activities | $75.7M | $31.5M | -$-5.74M | -$-73.76M | $5.88M |
| Investments in property, plant and equipment | $0.00 | -$-400K | -$-15M | -$-450K | -$-630K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-92.36M | $4.13M | -$-4.3M | $72.8M | -$-80.04M |
| Common stock issued | $8.1M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | -$-10M | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $600K | -$-11.64M | $18.4M | $6.55M | $62.7M |
| Net change in cash | -$-16.11M | $24M | $8.33M | $5.57M | -$-11.48M |
| Cash at end of period | $40.6M | $56.8M | $32.8M | $24.5M | $18.9M |
| Operating cash flow | $75.7M | $31.5M | -$-5.74M | -$-73.76M | $5.88M |
| Capital expenditure | $0.00 | -$-400K | -$-15M | -$-450K | -$-630K |
| Free cash flow | $75.7M | $31.1M | -$-20.74M | -$-74.21M | $5.25M |
Line items
Line items
Line items
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
- CEO
- Raul R. Rodriguez
- Employees
- 174
- Beta
- 1.13
Explore
Frequently asked questions
What is the intrinsic value of Rigel Pharmaceuticals, Inc. (RIGL)?
Rigel Pharmaceuticals, Inc. (RIGL) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is RIGL undervalued?
RIGL trades at a price of $40.09 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.